Pneumococcal Vaccine Market
Global Pneumococcal Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type (Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23), Others), By Distribution Channel (Public, and Private), By Type (Branded and Generic), By Age Group (Children and Adult) and Forecast, 2020-2026 Update Available - Forecast 2024-2030
The pneumococcal vaccine market is expected to show considerable growth at a CAGR of around 4.0% during the forecast period 2020-2026. Major factors for the growth of the market include high spending to curb pneumonia among children in the developed economies. Moreover, increasing healthcare infrastructure in the emerging economies, rising per capita healthcare expenditure, and growing awareness toward vaccination are also augmenting the market growth. In addition, innovations in the pneumonia vaccines are also providing significant opportunities to the market.
As per a report by John Hopkins, around 5.7 million children were died before attaining the age of 5 years in 2016 out of which nearly 25% were due to pneumonia or diarrhea. 15 countries, mainly in Asia and Africa have the most burden of pneumonia. As in 2018, 55% of the global under 5-year age population resides in these countries however they represent 70% of the global under-5 pneumonia and diarrhea deaths. The countries include China, India, Indonesia, Nigeria, Pakistan, the Democratic Republic of the Congo, Ethiopia, Chad, Angola, Somalia, Tanzania, Niger, Bangladesh, Uganda, and Côte d'Ivoire. Growth in the private healthcare expenditure in the emerging economies such as India, China, and Indonesia, and increasing investment by government and international organizations will provide a significant opportunity to the market.
GAVI (the Vaccine Alliance), is significantly working toward the children vaccination in the emerging economies. In June 2009, countries including Italy, UK, Canada, Russia, Norway, and Bill & Melinda Gates Foundation have contributed $1.5 billion for Gavi’s vaccination program, Advance Market Commitment (AMC). Due to this, in Gavi supported countries pneumonia vaccination coverage has increased to 48% in 2018 (higher than the global average of 47%), compared to 37% in 2015. By the end of 2018, more than 183 million children have been vaccinated against pneumococcal disease through Gavi. Moreover, two vaccine manufacturers have pledged to provide 1.65 billion doses through 2027. The prices of GAVI’s vaccine dose are also decreasing continuously. During the start of the AMC, the price of the vaccine for the Gavi was $3.5 per dose. After a new agreement with the Serum Institute of India in June 2020, the vaccine will price $2 per dose. Under the agreement, the company will provide 10 million PCV doses every year to Gavi supported countries for the next ten years.
Market Segmentation
The global pneumococcal vaccine market is segmented based on the vaccine type, by distribution channel, by type, and by age group. By vaccine type, the market is segmented into Pneumococcal Conjugate Vaccine (PCV13), Pneumococcal Polysaccharide Vaccine (PPSV23), and others. PCV13 is expected to have a major market share during the forecast period. PCV13 is the vaccine owned by Pfizer Inc., which generated revenue of $5.8 billion in 2019. By distribution channel, the market is segmented into public and private. The private sector will hold a major market share during the forecast period. By type, the market is segmented into branded and generic. Branded will have a major market share however generic will show a lucrative growth rate during the forecast period. By age group, the market is segmented into children and adults. Children's vaccination will maintain a major market share during the forecast period. PCV13 can be administrated to children and adults whereas PPSV23 is approved for children less than 2 years and adults above 50 years of age.
Global Pneumococcal Vaccine Market Share by Age Group, 2019 (%)
Regional Outlook
On the basis of geography, the global pneumococcal vaccine market is segmented based on four major regions, including North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America holds the largest market share owing to the high price of vaccination in the country. Alone, Pfizer Inc. generated revenue of $3.2 billion from the US market from Prevnar 13/Prevenar 13 sales in 2019.
However, significant market opportunities can be witnessed in Asia-Pacific. Increasing healthcare infrastructure, rising disposable income and increasing awareness toward vaccination are some of the major factors for the growth of the market in the region. Significant growth in the branded vaccines in China is expected to be a witness during the forecast period. Besides, a high volume will be witnessed in Asia-Pacific and Rest of the World in the pneumococcal vaccine market due to significant funding from GAVI however, the cost of the vaccine is much lower than the cost in developed economies.
Global Pneumococcal Vaccine Market Growth, by Region 2020-2026
Market Players Outlook
Few market players are dominating the pneumococcal vaccine market which includes Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Merck & Co., Inc., Walvax Biotechnology Co., Ltd., CSL Ltd., and Astellas Pharma Inc.. The market players are adopting growth strategies, including mergers and acquisitions, product launches, and partnerships & collaborations, to gain a competitive advantage in the market. For instance, in January 2020, the first Chinese pneumococcal 13-valent conjugate vaccine developed by Walvax Biotechnology Co., Ltd. was approved by the National Medical Products Administration. The new approval can end the monopoly of Pfizer Inc., in the PCV13 vaccine market.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Pneumococcal vaccine market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdowns
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. GlaxoSmithKline PLC
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Serum Institute of India Pvt. Ltd.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Merck & Co., Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Pfizer Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. CSL Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Pneumococcal Vaccine Market by Vaccine Type
5.1.1. Pneumococcal Conjugate Vaccine (PCV13)
5.1.2. Pneumococcal Polysaccharide Vaccine (PPSV23)
5.1.3. Other
5.2. Global Pneumococcal Vaccine Market by Distribution Channel
5.2.1. Public (Government & Non-Government)
5.2.2. Private
5.3. Global Pneumococcal Vaccine Market by Type
5.3.1. Branded
5.3.2. Generic
5.4. Global Pneumococcal Vaccine Market by Age Group
5.4.1. Children
5.4.2. Adult
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Astellas Pharma Inc.
7.2. China National Biotec Group Company Ltd.
7.3. CSL Ltd.
7.4. GlaxoSmithKline PLC
7.5. Merck & Co., Inc.
7.6. Novavax, Inc.
7.7. Pfizer Inc.
7.8. Walvax Biotechnology Co., Ltd.
7.9. SK Bioscience
7.10. Sanofi SA
7.11. Serum Institute of India Pvt. Ltd.
7.12. PnuVax Incorporated
1. GLOBAL PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2019-2026 ($ MILLION)
2. PNEUMOCOCCAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
3. PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
4. OTHER PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
5. GLOBAL PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
6. PUBLIC PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
7. PRIVATE PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
8. GLOBAL PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
9. BRANDED PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
10. GENERIC PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
11. GLOBAL PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2019-2026 ($ MILLION)
12. CHILDREN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
13. ADULT PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
14. NORTH AMERICAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
15. NORTH AMERICAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2019-2026 ($ MILLION)
7.13. NORTH AMERICAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
7.14. NORTH AMERICAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
7.15. NORTH AMERICAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2019-2026 ($ MILLION)
16. EUROPEAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
17. EUROPEAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2019-2026 ($ MILLION)
7.16. EUROPEAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
7.17. EUROPEAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
7.18. EUROPEAN PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2019-2026 ($ MILLION)
18. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
19. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2019-2026 ($ MILLION)
7.19. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
7.20. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
7.21. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2019-2026 ($ MILLION)
20. REST OF THE WORLD PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY VACCINE TYPE, 2019-2026 ($ MILLION)
7.22. REST OF THE WORLD PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2019-2026 ($ MILLION)
7.23. REST OF THE WORLD PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
7.24. REST OF THE WORLD PNEUMOCOCCAL VACCINE MARKET RESEARCH AND ANALYSIS BY AGE GROUP, 2019-2026 ($ MILLION)
1. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE BY VACCINE TYPE, 2019 VS 2026 (%)
2. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE BY DISTRIBUTION CHANNEL, 2019 VS 2026 (%)
3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE BY DISTRIBUTION TYPE, 2019 VS 2026 (%)
4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE BY AGE GROUP, 2019 VS 2026 (%)
5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
6. US PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
7. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
8. UK PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
9. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
10. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
11. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
12. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
13. REST OF EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
14. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
15. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
16. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
17. REST OF ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, 2019-2026 ($ MILLION)
